164 related articles for article (PubMed ID: 11825098)
1. Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants.
Leger F; Debord J; Le Meur Y; Rousseau A; Büchler M; Lachâtre G; Paintaud G; Marquet P
Clin Pharmacokinet; 2002; 41(1):71-80. PubMed ID: 11825098
[TBL] [Abstract][Full Text] [Related]
2. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients.
Saint-Marcoux F; Marquet P; Jacqz-Aigrain E; Bernard N; Thiry P; Le Meur Y; Rousseau A
Clin Pharmacokinet; 2006; 45(9):905-22. PubMed ID: 16928152
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
Schädeli F; Marti HP; Frey FJ; Uehlinger DE
Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
[TBL] [Abstract][Full Text] [Related]
5. Ciclosporin population pharmacokinetics and Bayesian estimation in thoracic transplant recipients.
Fruit D; Rousseau A; Amrein C; Rollé F; Kamar N; Sebbag L; Redonnet M; Epailly E; Marquet P; Prémaud A
Clin Pharmacokinet; 2013 Apr; 52(4):277-88. PubMed ID: 23400901
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator.
Rousseau A; Léger F; Le Meur Y; Saint-Marcoux F; Paintaud G; Buchler M; Marquet P
Ther Drug Monit; 2004 Feb; 26(1):23-30. PubMed ID: 14749545
[TBL] [Abstract][Full Text] [Related]
7. Application of a gamma model of absorption to oral cyclosporin.
Debord J; Risco E; Harel M; Le Meur Y; Büchler M; Lachâtre G; Le Guellec C; Marquet P
Clin Pharmacokinet; 2001; 40(5):375-82. PubMed ID: 11432538
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies.
Saint-Marcoux F; Knoop C; Debord J; Thiry P; Rousseau A; Estenne M; Marquet P
Clin Pharmacokinet; 2005; 44(12):1317-28. PubMed ID: 16372829
[TBL] [Abstract][Full Text] [Related]
9. Dose adjustment strategy for oral microemulsion formulation of cyclosporine: population pharmacokinetics-based analysis in kidney transplant patients.
Tokui K; Kimata T; Uchida K; Yuasa H; Hayashi Y; Itatsu T; Nabeshima T
Ther Drug Monit; 2004 Jun; 26(3):287-94. PubMed ID: 15167630
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.
Djebli N; Rousseau A; Hoizey G; Rerolle JP; Toupance O; Le Meur Y; Marquet P
Clin Pharmacokinet; 2006; 45(11):1135-48. PubMed ID: 17048977
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients.
Benkali K; Prémaud A; Picard N; Rérolle JP; Toupance O; Hoizey G; Turcant A; Villemain F; Le Meur Y; Marquet P; Rousseau A
Clin Pharmacokinet; 2009; 48(12):805-16. PubMed ID: 19902988
[TBL] [Abstract][Full Text] [Related]
13. Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis.
Rousseau A; Monchaud C; Debord J; Vervier I; Estenne M; Thiry P; Marquet P
Ther Drug Monit; 2003 Feb; 25(1):28-35. PubMed ID: 12548141
[TBL] [Abstract][Full Text] [Related]
14. Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients.
Bourgoin H; Paintaud G; Büchler M; Lebranchu Y; Autret-Leca E; Mentré F; Le Guellec C
Br J Clin Pharmacol; 2005 Jan; 59(1):18-27. PubMed ID: 15606436
[TBL] [Abstract][Full Text] [Related]
15. Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation.
Monchaud C; Rousseau A; Leger F; David OJ; Debord J; Dantoine T; Marquet P
Eur J Clin Pharmacol; 2003 Apr; 58(12):813-20. PubMed ID: 12698308
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients.
Chen YH; Zheng KL; Chen LZ; Dai YP; Fei JG; Qiu J; Li J
Transplant Proc; 2005 Dec; 37(10):4246-50. PubMed ID: 16387090
[TBL] [Abstract][Full Text] [Related]
17. Easy-to-use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation.
Langers P; Cremers SC; den Hartigh J; Rijnbeek EM; Ringers J; Lamers CB; van Hoek B
Aliment Pharmacol Ther; 2005 Mar; 21(5):549-57. PubMed ID: 15740538
[TBL] [Abstract][Full Text] [Related]
18. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporine monitoring in patients with renal transplants: two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure.
Primmett DR; Levine M; Kovarik JM; Mueller EA; Keown PA
Ther Drug Monit; 1998 Jun; 20(3):276-83. PubMed ID: 9631924
[TBL] [Abstract][Full Text] [Related]
20. Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods.
Prémaud A; Le Meur Y; Debord J; Szelag JC; Rousseau A; Hoizey G; Toupance O; Marquet P
Ther Drug Monit; 2005 Jun; 27(3):354-61. PubMed ID: 15905807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
